Excelsior Biopharma

Excelsior Biopharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Excelsior Biopharma (6496.TWO) as of Oct 28, 2026 is -174.16 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -82.79 M TWD — a change of 110.37% (lower).

EBITDA

-174.16 MTWD

YoY

110.37%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Excelsior Biopharma is 2025 -174.16 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Excelsior Biopharma was 2024 -82.79 M TWD. It decreases by 110.37% lower compared to the previous year.

The Excelsior Biopharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
282.09 M TWD
Jan 1, 2019
86.78 M TWD
Jan 1, 2020
46.78 M TWD
Jan 1, 2021
-1.02 M TWD
Jan 1, 2022
-25.82 M TWD
Jan 1, 2023
-80.83 M TWD
Jan 1, 2024
-82.79 M TWD
Jan 1, 2025
-174.16 M TWD
The Excelsior Biopharma EBITDA history
YEAREBITDAYoY
-174.16 MTWD+110.37%
-82.79 MTWD+2.43%
-80.83 MTWD+213.08%
-25.82 MTWD+2,433.56%
-1.02 MTWD-102.18%
46.78 MTWD-46.09%
86.78 MTWD-69.24%
282.09 MTWD-13.41%
325.78 MTWD+51.17%
215.51 MTWD+23.07%
175.11 MTWD-10.62%
195.93 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Excelsior Biopharma Stock analysis

What does Excelsior Biopharma do? Excelsior Biopharma Inc., headquartered in Taipei City, Taiwan, operates in the Health Care sector. The company focuses on the research, development, manufacturing, and distribution of pharmaceutical products, including prescription and non-prescription drugs, health care products, medical equipment, and rapid test reagents. Listed on 19 December 2014, Excelsior Biopharma serves both domestic and international markets with its diverse product portfolio. Excelsior Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Excelsior Biopharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Excelsior Biopharma is -174.16 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Excelsior Biopharma changed from -82.79 M TWD to -174.16 M TWD, representing a 110.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Excelsior Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Excelsior Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Excelsior Biopharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Excelsior Biopharma